BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu T, Li L, Liu YC, Cao W, Chen JS, Hu S, Liu Y, Li LY, Zhou H, Meng XM, Huang C, Zhang L, Li J, Zhou H. CRISPR/Cas9-related technologies in liver diseases: from feasibility to future diversity. Int J Biol Sci 2020;16:2283-95. [PMID: 32760197 DOI: 10.7150/ijbs.33481] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Piergentili R, Del Rio A, Signore F, Umani Ronchi F, Marinelli E, Zaami S. CRISPR-Cas and Its Wide-Ranging Applications: From Human Genome Editing to Environmental Implications, Technical Limitations, Hazards and Bioethical Issues. Cells 2021;10:969. [PMID: 33919194 DOI: 10.3390/cells10050969] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Bhardwaj S, Kesari KK, Rachamalla M, Mani S, Ashraf GM, Jha SK, Kumar P, Ambasta RK, Dureja H, Devkota HP, Gupta G, Chellappan DK, Singh SK, Dua K, Ruokolainen J, Kamal MA, Ojha S, Jha NK. CRISPR/Cas9 gene editing: New hope for Alzheimer's disease therapeutics. Journal of Advanced Research 2021. [DOI: 10.1016/j.jare.2021.07.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
3 Maestro S, Weber ND, Zabaleta N, Aldabe R, Gonzalez-Aseguinolaza G. Novel vectors and approaches for gene therapy in liver diseases. JHEP Rep 2021;3:100300. [PMID: 34159305 DOI: 10.1016/j.jhepr.2021.100300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]